FDA Approves First Blood Test for Early Detection of Alzheimer's Disease

Strategic Insights -

The U.S. Food and Drug Administration (FDA) has granted marketing clearance to the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, a blood test designed to detect Alzheimer disease in patients aged 55 and older who are showing signs of the disease. This breakthrough diagnostic tool measures the levels of two serum proteins, pTau217 and β-amyloid 1-42, and calculates a numerical ratio to determine the presence of amyloid plaques in the brain. The test replaces the need for invasive lumbar punctures and positron emission tomography (PET) scans, requiring only a simple blood sample.

Key Takeaways:

  • The Lumipulse test measures the plasma ratio of pTau217 and β-amyloid 1-42 to detect Alzheimer disease in patients aged 55 and older.
  • The test has been granted marketing clearance for patients in specialized care settings who exhibit signs and symptoms of cognitive decline.
  • In a multicenter clinical study, the Lumipulse test showed 91.7% sensitivity and 97.3% specificity in detecting amyloid plaques in patients.
  • Less than 20% of test results were indeterminate, and results should be interpreted alongside other relevant clinical information.
  • The FDA has approved the Lumipulse test for patients in specialized care settings, highlighting the need for early detection and treatment of Alzheimer's disease.
  • Nearly 7 million Americans are living with Alzheimer's disease, and the number is projected to rise to nearly 13 million.

Statistics:

  • 91.7% sensitivity in detecting amyloid plaques in patients with the Lumipulse test
  • 97.3% specificity in detecting amyloid plaques in patients with the Lumipulse test
  • Less than 20% of test results were indeterminate
  • Nearly 13 million Americans are projected to be living with Alzheimer's disease by 2030
  • 7 million Americans are currently living with Alzheimer's disease
  • The Lumipulse test has been granted marketing clearance for patients aged 55 and older

Sources:

  • Stephanie Brown HealthDay Reporter, FRIDAY, May 16, 2025 (HealthDay News)
  • FDA Center for Devices and Radiological Health
  • Alzheimer's Drug Discovery Foundation
  • Michelle Tarver, M.D., Ph.D.
  • Howard Fillit, M.D., M.S.